脓毒症表型分型与个体化绝对风险差异的关系:两项多中心试验中两种方法的二次分析
该研究是对ProCESS和ARISE两项多中心试验的二次分析,纳入829例ProCESS和1588例ARISE脓毒症休克成人患者,应用临床亚型(α、β、γ、δ)和生物学亚表型(高炎症和非高炎症)进行分型,并使用监督学习预测个体化绝对风险差异(iARDs),主要结局为90天死亡率。结果显示,EGDT的平均治疗效应在临床和生物学亚表型内均有变异,EGDT在β和非高炎症亚表型中可能有益,在γ和高炎症亚表型中可能有害,但各亚组内预测的iARDs范围从显著有害到显著有益。例如β亚型中EGDT平均死亡率降低8.5%(95%CI,-0.4至17.5),但iARDs范围从死亡率增加29%到降低16%,39%的患者预测受到伤害。结论认为,尽管表型分型可识别平均治疗效应有益或有害的亚组,但亚组内个体风险和获益仍差异巨大,提示表型分型可能无法可靠或安全地实现脓毒症个体化治疗。
要点
- 在β亚型中,EGDT平均死亡率降低8.5%(95%CI,-0.4至17.5),但个体化绝对风险差异范围从死亡率增加29%到降低16%,39%的患者预测受到伤害。
- EGDT在β和非高炎症亚表型中可能有益,在γ和高炎症亚表型中可能有害。
- 各亚组内预测的个体化绝对风险差异范围从显著有害到显著有益,变异极大。
- 研究纳入829例ProCESS和1588例ARISE脓毒症休克成人患者,来自全球81个中心。
- 作者认为,表型分型可能无法可靠或安全地实现脓毒症个体化治疗。
适用人群与场景
- 成人脓毒症休克患者,来自ProCESS试验829例和ARISE试验1588例;其中363例ProCESS患者有生物标志物数据用于生物学亚表型分析。
研究设计与关键结果
- 研究类型:ProCESS和ARISE两项多中心试验的二次分析,共纳入829例ProCESS和1588例ARISE脓毒症休克成人患者,来自全球81个中心。
- 干预与对照:早期目标导向治疗(EGDT)或常规治疗。
- 主要终点:90天死亡率;使用监督学习预测个体化绝对风险差异(iARDs)。
- EGDT在β亚型中平均死亡率降低8.5%(95%CI,-0.4至17.5),但iARDs范围从死亡率增加29%到降低16%,39%的患者预测受到伤害。
- EGDT在β和非高炎症亚表型中可能有益,在γ和高炎症亚表型中可能有害。
- 各亚组内预测的iARDs范围从显著有害到显著有益。
证据类型、等级与局限
- 证据类型:两项多中心随机对照试验(ProCESS和ARISE)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管临床和生物学表型分型可识别平均治疗效应有益或有害的亚组,但亚组内个体风险和获益仍差异巨大,表型分型可能无法可靠或安全地实现脓毒症个体化治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Sepsis trials likely include patients who vary in response to therapeutic interventions. The optimal approach to identify such differences in treatment response remains unclear. Estimating individualized absolute risk differences (iARDs) to model treatment response at an individual patient level using supervised effect models applied to randomized trial data may be informative. We explored the relationship between two subgrouping approaches and a recently published iARD model for the effect of early goal-directed therapy (EGDT) resuscitation in sepsis.
DESIGN: Secondary analysis of the Protocolized Care for Early Septic Shock (ProCESS) and Australasian Resuscitation in Sepsis Evaluation (ARISE) trials. We applied clinical subtypes (α, β, γ, δ) to 829 ProCESS and 1588 ARISE patients and biologic "hyperinflammatory" and "nonhyperinflammatory" subphenotypes to 363 ProCESS patients with biomarker data using established methods. We predicted iARDs with supervised learning using clinical variables as predictors and 90-day mortality as the primary outcome. We evaluated iARD variability within subgroups.
SETTING: Eighty-one sites worldwide.
PATIENTS/SUBJECTS: Adults with septic shock.
INTERVENTIONS: EGDT or usual care.
MEASUREMENTS AND MAIN RESULTS: The average treatment effect of EGDT appeared to vary within both clinical and biologic subphenotypes. EGDT appeared potentially beneficial in the β and nonhyperinflammatory subphenotypes but harmful in the γ and hyperinflammatory subphenotypes. However, the predicted iARDs within each subgroup ranged from considerable harm to considerable benefit. For example, for the β-subtype, the average mortality reduction from EGDT was 8.5% (95% CI, -0.4 to 17.5), but the iARDs ranged from a 29% increase to a 16% reduction in mortality, with 39% of patients predicted to be harmed.
CONCLUSIONS: Although both clinical and biologic phenotyping may identify subgroups whose average treatment effect is beneficial or harmful, individual risks and benefits within subgroups still vary dramatically, raising concern that phenotyping may not reliably or safely personalize sepsis care.
参考来源
- Talisa VB, Yende SP, Angus DC, et al. Relationship Between Phenotyping and Individualized Absolute Risk Differences in Sepsis: A Secondary Analysis of Two Approaches in Two Multicenter Trials. Crit Care Explor. 2025. PMID: 41098209. doi:10.1097/CCE.0000000000001332
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。